The "NEW" Oil and Gas Crisis: Lack Of Lithium
We are in a global lithium crisis that's going to get far worse. Just like OPEC and Russia control the price and supply of oil and gas, China has the U.S. in a chokehold when it comes to lithium.
Click here to see how the prices may explode

CHM Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$2,940.00
Insider Selling (Last 12 Months): A$0.00

Chimeric Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Chimeric Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Chimeric Therapeutics Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 03/11/2021 11:04 AM ET

This chart shows the closing price history over time for CHM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Chimeric Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/18/2022Jennifer ChowInsiderIssued17,222,368A$0.09A$1,498,346.02
6/29/2022Leslie (Mi Ok) ChongInsiderBuy30,000A$0.10A$2,940.00
3/25/2022Leslie (Mi Ok) ChongInsiderIssued3,905A$0.15A$585.75
8/4/2021George MatchamInsiderBuy500,000A$0.33A$166,000.00
3/8/2021Cynthia ElkinsInsiderBuy24,800A$0.32A$7,886.40
See Full Table

SEC Filings (Institutional Ownership Changes) for Chimeric Therapeutics (ASX:CHM)

Chimeric Therapeutics logo
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.
Read More on Chimeric Therapeutics

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Chimeric Therapeutics?

Chimeric Therapeutics' top insider shareholders include:
  1. Cynthia Elkins (Insider)
  2. George Matcham (Insider)
  3. Jennifer Chow (Insider)
  4. Leslie (Mi Ok) Chong (Insider)
Learn More about top insider investors at Chimeric Therapeutics.
The "NEW" Oil and Gas Crisis: Lack Of Lithium
We are in a global lithium crisis that's going to get far worse. Just like OPEC and Russia control the price and supply of oil and gas, China has the U.S. in a chokehold when it comes to lithium.
Click here to see how the prices may explode